Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The trial was conducted between April 2006 and April 2008 in 9 European countries at 58 investigational sites. The countries participating were: Austria, Belgium, France, Germany, Italy, The Netherlands, Portugal, Switzerland, and United Kingdom.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	Olemesartan 20 mg to start. Hydrochlorothiazide 12.5 mg and then 25 mg was added, if necessary. If blood pressure goal was still not achieved, amlodipine 5 mg and then 10 mg were added, if needed. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg.

Participant Flow:   Overall Study

	Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed
STARTED	694
COMPLETED	601 [1]
NOT COMPLETED	93
Adverse Event	21
Withdrawal by Subject	17
Did not meet entry criteria	55

Reporting Groups

	Description
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	Olemesartan 20 mg to start. Hydrochlorothiazide 12.5 mg and then 25 mg was added, if necessary. If blood pressure goal was still not achieved, amlodipine 5 mg and then 10 mg were added, if needed. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg.

Baseline Measures

	Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed
Number of Participants   [units: participants]	694
Age   [units: years] Mean ± Standard Deviation	58.16  ± 12.06
Gender   [units: participants]
Female	337
Male	357
Region of Enrollment   [units: participants]
Portugal	12
France	121
Belgium	94
Austria	35
Netherlands	43
Germany	207
United Kingdom	141
Italy	35
Switzerland	6
Weight   [units: kg] Mean ± Standard Deviation	82.16  ± 16.09
Body Mass Index   [units: kg/m^2] Mean ± Standard Deviation	28.86  ± 4.69
Ethnicity   [units: Participants]
Caucasian	678
Black	13
Asian	3

1.  Primary:

The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.   [ Time Frame: Baseline to ≤20 weeks ]

2.  Secondary:

Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved   [ Time Frame: Baseline to ≤20 weeks ]

3.  Secondary:

Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.   [ Time Frame: Baseline to ≤20 weeks ]

4.  Secondary:

Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved   [ Time Frame: Baseline to ≤20 weeks ]

5.  Secondary:

Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment   [ Time Frame: Baseline to ≤20 weeks ]

6.  Secondary:

Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment   [ Time Frame: Baseline to ≤20 weeks ]